Loading...
Docoh

EQRx (EQRX)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On December 16, 2021, CM Life Sciences III Inc., a Delaware corporation (“CMLS III”), held a Special Meeting of its stockholders (the “Special Meeting”). At the Special Meeting, a total of 53,077,371 (approximately 76.92%) of CMLS III’s issued and outstanding shares of common stock held of record as of November 4, 2021, the record date for the Special Meeting, were present either in person or represented by proxy, which constituted a quorum. CMLS III’s stockholders voted on the following proposals at the Special Meeting, each of which was approved. The final vote tabulation for each proposal is set forth below.

(a)Proposal No. 1 — The Business Combination Proposal — to approve and adopt the Agreement and Plan of Merger, dated as of August 5, 2021, as amended by Amendment No. 1 and Amendment No. 2 thereto (the “amendments”), dated as of September 21, 2021 and October 28, 2021, respectively (as so amended and as may be further amended and/or restated from time to time, the “Merger Agreement”), by and among CMLS III, its wholly owned subsidiary, Clover III Merger Sub, Inc. (“Merger Sub”), and EQRx, Inc. (“EQRx”), a composite copy of which, incorporating the amendments into the text of the initial agreement, is attached to the Definitive Proxy Statement, as filed December 1, 2021, as Annex A, and approve the transactions contemplated thereby (“Business Combination”), including the merger of Merger Sub with and into EQRx, with EQRx surviving the merger as a wholly owned subsidiary of CMLS III, and the issuance of common stock to EQRx stockholders as merger consideration:

Class A Shares Votes ForVotes AgainstAbstentions
36,260,0983,017,9272,345
Class B Shares Votes ForVotes AgainstAbstentions
13,800,00000

(b)Proposal No. 2 — The Nasdaq Stock Issuance Proposal — to approve, assuming the Business Combination Proposal is approved, and for purposes of complying with applicable listing rules of the Nasdaq Stock Market (“Nasdaq”), the issuance of more than 20% of CMLS III’s outstanding common stock in connection with the Business Combination and subscription agreements dated as of August 5, 2021 with certain institutional investors (collectively, the “PIPE Investors”), including up to 120,000,000 shares of our common stock to the PIPE Investors, which includes affiliates of CMLS Holdings III LLC (“Sponsor”) that subscribed for 10,250,000 shares of common stock, and up to 365,000,000 shares of our common stock to EQRx stockholders and up to 50,000,000 Earn-Out Shares:

Class A Shares Votes ForVotes AgainstAbstentions
36,256,9973,017,3406,033
Class B Shares Votes ForVotes AgainstAbstentions
13,800,00000


(c)Proposal No. 3 — The Incentive Plan Proposal — to approve the EQRx, Inc. 2021 Stock Option and Incentive Plan, a copy of which is attached to the Definitive Proxy Statement filed December 1, 2021, as Annex C (“2021 Incentive Plan”), including the authorization of the initial share reserve under the Incentive Plan:

Class A Shares Votes ForVotes AgainstAbstentions
32,605,6316,649,63825,101
Class B Shares Votes ForVotes AgainstAbstentions
13,800,00000

(d)Proposal No.4 — The ESPP Proposal  — to approve the EQRx, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the Definitive Proxy Statement filed December 1, 2021 as Annex D (“ESPP”), including the authorization of the initial share reserve under the ESPP:

Class A Shares Votes ForVotes AgainstAbstentions
32,952,9626,304,62822,780
Class B Shares Votes ForVotes AgainstAbstentions
13,800,00000

(e)Proposal No. 5 — The Charter Amendment Proposal — to, assuming the Business Combination Proposal is approved, adopt the A&R Certificate of Incorporation in the form attached to the Definitive Proxy Statement filed December 1, 2021 as Annex E:

Class A Shares Votes ForVotes AgainstAbstentions
36,248,5693,024,9966,805
Class B Shares Votes ForVotes AgainstAbstentions
13,800,00000